Introduction Patients with various advanced cancers devoid of nuclear progesterone
receptors (nPR) have demonstrated increased quality and length of life when treated with …

The most recent successful advances in lung cancer therapy have directly and increasingly
focused on personalized tumor genetic/epigenetic/immunologic profiling, and the …

Progesterone induced blocking factor (PIBF) is a unique protein that is not present in normal
cells, but is found predominantly in rapidly growing cells of the fetal placental unit or cancer …

Mifepristone treatment for advanced cancer has demonstrated considerable improvement in
both length and quality of life in patients who no longer have any other treatment options …

Cancer and the fetal-placental semi-allograft share certain characteristics, eg, rapid
proliferation, the capacity to invade normal tissue, and, related to the presence of antigens …

Background: There is evidence that a unique immunomodulatory protein, known as the
progesterone induced blocking factor (PIBF), is utilized by a large variety of cancers to …

Though representing only, a minority of cases of non-small cell lung cancer (NSCLC), the
presence of the epidermal growth factor receptor (EGFR) mutation is associated with a better …

Glioma is the most common and aggressive primary tumor of the central nervous system.
The standard treatment for malignant gliomas is surgery followed by chemoradiotherapy …

The classification and treatment of breast cancer is largely defined by the expression of
steroid hormone receptors (HRs), namely estrogen receptor (ER) and progesterone receptor …

Objective. To explore the effect of eye movement training on sleep quality of patients with
advanced lung cancer based on the Pittsburgh Sleep Quality Index (PSQI). Methods. 120 …